The forum featured 16 distinguished experts from leading institutions across Asia. Speakers from Japan, Korea, Malaysia, Singapore, and Taiwan shared regional insights and practical experiences in clinical trials.The event provided a valuable platform for professionals and students to explore emerging trends and foster cross-border exchange.

Alongside the global impact of the COVID-19 pandemic, the GCP Renovation initiative and rapid advances in information technology are significantly transforming how clinical trials are conducted. Amid these dynamic changes, the academic role is also evolving through a more horizontally collaborative model.

Due to the global COVID-19 pandemic, the event was held in a hybrid format, combining both in-person and online participation. Over 20 experts with outstanding experience and achievements in clinical trials from South Korea, Japan, Malaysia, Thailand, and other countries were invited as speakers. Domestic scholars also joined the event to engage in discussions, which sparked many potential collaborations in clinical trials.

At the 2019 REACTA Forum in Japan, the network convened to explore key themes shaping the future of clinical research in Asia. Twenty leading experts shared insights on five emerging topics, including regenerative medicine, clinical strategies in Asia, and diseases specific to the region. The forum also featured proposals to advance investigator-initiated registry trials targeting conditions prevalent across Asia. This gathering marked a pivotal moment in strengthening REACTA’s commitment to cross-border collaboration and clinical trial innovation.

Due to the global COVID-19 pandemic, the event was held in a hybrid format, combining both in-person and online participation. Over 20 experts with outstanding experience and achievements in clinical trials from South Korea, Japan, Malaysia, Thailand, and other countries were invited as speakers. Domestic scholars also joined the event to engage in discussions, which sparked many potential collaborations in clinical trials.

The 2017 Regional Asian Clinical Trial Association (REACTA) conference was held in Malaysia from September 27 to 29. Taipei Medical University (TMU) was represented by Dr. Hsien-Ying Sung, Deputy Director of the Joint Clinical Trial Center, and Dr. Kuan-Chou Chen, Director of the Institute of Clinical Medicine. The conference mainly discussed the clinical trial development experiences of member countries over the past four to five years, and it was hoped that from this year onward, there would be greater collaboration on multi-country, multi-center physician-initiated clinical trials (PI-initiated Trials, IITs).

The conference agenda was structured into four key sections: (1) Latest Regulatory Trends; (2) Changes, Challenges, and Opportunities in the Development of Clinical Trials in Asia; (3) Institutional Management and Early-Phase Clinical Trials; and (4) Group Discussions and Project Proposals.

For the next step, for the patients,Understanding and Collaboration between Regulatory Agency and ARO.

To promote communication between industry and clinical trial centers in Asia, in order to increase standards and share important insights.